Actively Recruiting
Phase II Study of Cemiplimab and Fianlimab Before Kidney Surgery in People With Locally Advanced Clear Cell Kidney Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-04
10
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether it is practical and safe to give cemiplimab and fianlimab before a nephrectomy surgery in people with locally advanced clear cell renal cell carcinoma, a type of kidney cancer. They want to see if this immunotherapy treatment causes any delays in surgery and if it affects the size of the tumor before the planned operation. This is a pilot phase II study assessing these treatments before surgery. Participants will receive cemiplimab and fianlimab through intravenous infusions every 3 weeks, for a total of three treatments unless side effects, disease progression, or withdrawal occur earlier. All patients in the study will follow this treatment schedule before undergoing nephrectomy surgery. The study focuses on neoadjuvant immunotherapy, meaning treatment given before surgery. During the trial, participants will be monitored for safety and treatment response, including changes in tumor size. Researchers will evaluate the response one year after starting treatment. Participants must undergo various assessments including imaging scans and lab tests before treatment begins. The total study period includes the treatment phase and follow-up to assess outcomes and safety, lasting until about a year after treatment starts.
CONDITIONS
Brief Title
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Research Team
M
Martin Voss, MD
A
Abraham Hakimi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here